EUVIMEDEUVIMED entdecken
Crossref

Predictors of eGFR Decline Following Treatment for Primary Aldosteronism

Dr Karanjeet S. Chauhan, Senesha Kumarage, Prof Peter J. Fuller, Prof Peter G Kerr, Dr Jessica Ryan, Dr Fumiko Katsuragawa, A/Prof Jun Yang, Dr Renata Libianto

Australasian Journal of Clinical Nephrology · 29.05.2026 · 1 (1)

DOI: 10.64945/ts9pr242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australasian Journal of Clinical Nephrology, online erschienen am 29.05.2026. Verfasst von Dr Karanjeet S. Chauhan und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Primary aldosteronism (PA) is the most common cause of secondary hypertension and is associated with significant cardiovascular and renal morbidity. Treatment with mineralocorticoid receptor antagonists (MRA) or adrenalectomy often leads to an early decline in estimated glomerular filtration rate (eGFR), which may be misinterpreted as renal injury rather than the correction of aldosterone-induced hyperfiltration. This study aimed to evaluate renal function changes following PA treatment and to identify predictors of eGFR decline.

Methods

A retrospective cohort study was conducted involving patients with confirmed or probable PA who attended a tertiary endocrine hypertension clinic between July 2016 and June 2023. Clinical and biochemical parameters were collected at baseline and at follow-up clinic visits after treatment. Patients were grouped according to treatment modality (MRA or adrenalectomy). Longitudinal changes in eGFR and urine albumin-to-creatinine ratio (ACR) were analysed, and multivariable regression was performed to identify independent predictors of eGFR decline.

Results

Of 421 patients, 339 (81%) received MRA therapy and 82 (19%) underwent adrenalectomy. Both groups demonstrated a modest eGFR reduction at 12-24 months, with median declines of 4 mL/min/1.73 m² and 6 mL/min/1.73 m² respectively, followed by stabilisation at long-term follow-up. Albuminuria improved significantly in both groups, with median ACR decreasing from 1.7 to 1.0 mg/mmol in the MRA group and from 2.2 to 0.7 mg/mmol after adrenalectomy (p

Zitieren

APA

Chauhan, D. K. S., Kumarage, S., Fuller, P. P. J., Kerr, P. P. G., Ryan, D. J., Katsuragawa, D. F., Yang, A. J., & Libianto, D. R. (2026). Predictors of eGFR Decline Following Treatment for Primary Aldosteronism. Australasian Journal of Clinical Nephrology, 1(1). https://doi.org/10.64945/ts9pr242

Vancouver

Chauhan DKS, Kumarage S, Fuller PPJ, Kerr PPG, Ryan DJ, Katsuragawa DF, et al. Predictors of eGFR Decline Following Treatment for Primary Aldosteronism. Australasian Journal of Clinical Nephrology. 2026;1(1). doi:10.64945/ts9pr242

BibTeX
@article{Chauhan2026,
  author = {Chauhan, Dr Karanjeet S. and Kumarage, Senesha and Fuller, Prof Peter J. and Kerr, Prof Peter G and Ryan, Dr Jessica and Katsuragawa, Dr Fumiko and Yang, A/Prof Jun and Libianto, Dr Renata},
  title = {Predictors of eGFR Decline Following Treatment for Primary Aldosteronism},
  journal = {Australasian Journal of Clinical Nephrology},
  year = {2026},
  volume = {1},
  number = {1},
  doi = {10.64945/ts9pr242}
}
Kostenlos starten →